Table 5. Correlation between KRAS mutation in tissue samples and KRAS overexpression in CTC.
KRAS overexpression CTC | Total | ||||
---|---|---|---|---|---|
Negative | Positive | ||||
K-RAS tissue | Wild type | Count | 10 | 10 | 20 |
% within KRAS tissue | 50.0% | 50.0% | 100.0% | ||
% within KRAS overexpression CTC | 47.6% | 62.5% | 54.1% | ||
% of total | 27.0% | 27.0% | 25.0% | ||
Mutated | Count | 11 | 6 | 17 | |
% within KRAS tissue | 64.7% | 35.3% | 100.0% | ||
% within KRAS overexpression CTC | 52.4% | 37.5% | 45.9% | ||
% of total | 29.7% | 16.2% | 45.9% | ||
Total | Count | 21 | 6 | 37 | |
% within KRAS tissue | 56.8% | 43.2% | 100.0% | ||
% within KRAS overexpression CTC | 100.0% | 100.0% | 100.0% | ||
% of total | 56.8% | 43.2% | 100.0% |